Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands

Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR‐ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Shibata, Norihito, Miyamoto, Naoki, Nagai, Katsunori, Shimokawa, Kenichiro, Sameshima, Tomoya, Ohoka, Nobumichi, Hattori, Takayuki, Imaeda, Yasuhiro, Nara, Hiroshi, Cho, Nobuo, Naito, Mikihiko
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5543464/
https://ncbi.nlm.nih.gov/pubmed/28556300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13284
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados